Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $12 to $15.
Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $12 to $15.